More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

The biotech, renowned for its pioneering development of vaccines ... could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

Moderna has reported preliminary clinical ... "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel.

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...